|
MAP7D3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.11022302462516E-16 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-16 |
| Normal-vs-Stage2 |
7.20220549865758E-11 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62436730732907E-12 |
| Stage1-vs-Stage2 |
2.363900E-02 |
| Stage1-vs-Stage3 |
2.836200E-01 |
| Stage1-vs-Stage4 |
6.341500E-03 |
| Stage2-vs-Stage3 |
1.774220E-02 |
| Stage2-vs-Stage4 |
2.247300E-04 |
| Stage3-vs-Stage4 |
1.369010E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62436730732907E-12 |
| Normal-vs-AfricanAmerican |
9.03970009957789E-10 |
| Normal-vs-Asian |
1.62503344114384E-12 |
| Caucasian-vs-AfricanAmerican |
7.734000E-01 |
| Caucasian-vs-Asian |
9.599600E-01 |
| AfricanAmerican-vs-Asian |
8.233200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62447832963153E-12 |
| Normal-vs-Female |
1.62481139653892E-12 |
| Male-vs-Female |
3.028200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.22044604925031E-16 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
8.10220000000417E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.956000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.333000E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.338800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.608800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.556000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.692200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.16789999999412E-05 |
| Classical-VS-Follicular |
7.704700E-03 |
| Classical-VS-Other |
5.354200E-01 |
| Classical-VS-Normal |
6.66133814775094E-16 |
| Tall-VS-Follicular |
9.52409999754877E-08 |
| Tall-VS-Other |
1.527970E-01 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
1.986030E-01 |
| Follicular-VS-Normal |
4.86999329751825E-12 |
| Other-VS-Normal |
2.33139999999965E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
2.255900E-02 |
|
|
